{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:10:45Z","timestamp":1767139845289,"version":"build-2065373602"},"reference-count":51,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Amikacin is the antibiotic of choice for the treatment of Gram-negative infections, namely, those in neutropenic oncology patients. No populational pharmacokinetic studies are currently available reporting amikacin pharmacokinetics in neutropenic oncology patients despite their specific pathophysiological features and treatments. A large-scale retrospective study was herein conducted to specifically investigate the effects that tumor diseases have on the pharmacokinetic parameters of amikacin and identify whether chemotherapy, the lag time between administration of chemotherapy and amikacin, age and renal function contribute to amikacin pharmacokinetics in neutropenic cancer patients. A total of 1180 pharmacokinetic analysis from 629 neutropenic patients were enrolled. The daily dose administered to oncology patients was higher than that administered to non-oncology patients (p &lt; 0.0001). No statistical differences were found in amikacin concentrations, probably because drug clearance was increased in cancer patients (p &lt; 0.0001). Chemotherapy influenced amikacin pharmacokinetics and drug clearance decreased as the lag time enhanced. The elderly group revealed no statistical differences between the doses administered to both the oncology groups, suggesting that the impact of ageing is stronger than chemotherapy. Our research suggests that cancer patients require higher initial doses of amikacin, as well as when chemotherapy is received less than 30 days before amikacin treatment has started.<\/jats:p>","DOI":"10.3390\/antibiotics12020373","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T03:28:46Z","timestamp":1676258926000},"page":"373","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0620-7275","authenticated-orcid":false,"given":"Maria","family":"Aquino","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"}]},{"given":"Maria","family":"Tinoco","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-1671","authenticated-orcid":false,"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"CIBIT\u2014Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3854-6549","authenticated-orcid":false,"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"CIBIT\u2014Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, 3000-548 Coimbra, Portugal"}]},{"given":"Mar\u00edlia","family":"Rocha","sequence":"additional","affiliation":[{"name":"Centro Hospitalar e Universit\u00e1rio de Coimbra (CHUC, EPE), 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"CIBIT\u2014Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, 3000-548 Coimbra, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103709","DOI":"10.1016\/j.critrevonc.2022.103709","article-title":"Effectiveness of cognitive behavioral therapy in improving functional health in cancer survivors: A systematic review and meta-analysis","volume":"175","author":"Blumenstein","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.5888\/pcd18.210006","article-title":"Cancer Incidence Projections in the United States Between 2015 and 2050","volume":"18","author":"Weir","year":"2021","journal-title":"Prev. Chronic Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11912-022-01192-5","article-title":"Neutropenia and Infection Prophylaxis in Childhood Cancer","volume":"24","author":"Villeneuve","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/MCC.0000000000000978","article-title":"Severe infections in recipients of cancer immunotherapy: What intensivists need to know","volume":"28","author":"Joseph","year":"2022","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","article-title":"Current challenges of hematologic complications due to immune checkpoint blockade: A comprehensive review","volume":"101","author":"Ghanem","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_7","first-page":"741","article-title":"Oncologic Emergencies: Recognition and Initial Management","volume":"97","author":"Higdon","year":"2018","journal-title":"Am. Fam. Physician"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/0974-2727.163126","article-title":"Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients","volume":"7","author":"Lakshmaiah","year":"2015","journal-title":"J. Lab. Physicians"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","article-title":"Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?","volume":"27","author":"Boccia","year":"2022","journal-title":"Oncologist"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1128\/AAC.02561-14","article-title":"Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia","volume":"58","author":"Rosa","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1517\/14656566.2015.1055248","article-title":"Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors","volume":"16","author":"Koinis","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ajem.2021.09.055","article-title":"Emergency management of fever and neutropenia in children with cancer: A review","volume":"50","author":"Pulcini","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14656566.2011.541155","article-title":"Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia","volume":"12","author":"Saloustros","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13027-021-00387-y","article-title":"Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: The perspective from a developing country","volume":"16","author":"James","year":"2021","journal-title":"Infect. Agent Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5414\/CP203793","article-title":"Covariates of amikacin disposition in a large pediatric oncology cohort","volume":"59","author":"Dewandel","year":"2021","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40262-016-0428-x","article-title":"Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies","volume":"56","author":"Marsot","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Duong, A., Simard, C., Wang, Y., Williamson, D., and Marsot, A. (2021). Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?. Antibiotics, 10.","DOI":"10.20944\/preprints202104.0416.v1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e02098-19","DOI":"10.1128\/AAC.02098-19","article-title":"Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy","volume":"64","author":"Delzor","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-019-00828-3","article-title":"Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology","volume":"59","author":"Solans","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/FTD.0000000000000940","article-title":"Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range","volume":"44","author":"Brady","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10096-019-03769-8","article-title":"Diagnostic and medical needs for therapeutic drug monitoring of antibiotics","volume":"39","author":"Mabilat","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13613-021-00917-2","article-title":"Antimicrobial stewardship, therapeutic drug monitoring and infection management in the ICU: Results from the international A- TEAMICU survey","volume":"11","author":"Lanckohr","year":"2021","journal-title":"Ann. Intensiv. Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nephro.2018.08.004","article-title":"Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen","volume":"15","author":"Chaabane","year":"2019","journal-title":"Nephrol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0891-5520(03)00057-6","article-title":"Pharmacodynamics and dosing of aminoglycosides","volume":"17","author":"Turnidge","year":"2003","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1136\/ejhpharm-2021-003049","article-title":"Therapeutic drug monitoring of amikacin: Quantification in plasma by liquid chromatography-tandem mass spectrometry and work experience of clinical pharmacists","volume":"29","author":"Xu","year":"2022","journal-title":"Eur. J. Hosp. Pharm"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Alhameed, A.F., Al Khansa, S., Hasan, H., Ismail, S., and Aseeri, M. (2019). Bridging the Gap between Theory and Practice; the Active Role of Inpatient Pharmacists in Therapeutic Drug Monitoring. Pharmacy, 7.","DOI":"10.3390\/pharmacy7010020"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.2215\/CJN.08140718","article-title":"Clinical Pharmacology of Antibiotics","volume":"14","author":"Eyler","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_30","unstructured":"Gilbert, D.N., Moellering, R.C., Eliopoulos, G.M., and Chambers, M.D. (2010). The Sanford Guide to Antimicrobial Therapy 2010, Antimicrobial Therapy, Inc.. [40th ed.]."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijantimicag.2015.02.009","article-title":"Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations","volume":"46","author":"Roger","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00993-19","DOI":"10.1128\/AAC.00993-19","article-title":"Amikacin Initial Dose in Critically Ill Patients: A Nonparametric Approach To Optimize A Priori Pharmacokinetic\/Pharmacodynamic Target Attainments in Individual Patients","volume":"63","author":"Boidin","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1592\/phco.25.4.491.61034","article-title":"Clinical practice guidelines in nephrology: Evaluation, classification, and stratification of chronic kidney disease","volume":"25","author":"Bailie","year":"2005","journal-title":"Pharmacotherapy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.06.015","article-title":"Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences","volume":"129","author":"Bellesoeur","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jiac.2019.12.019","article-title":"The characteristics and impact indicator of vancomycin pharmacokinetics in cancer patients complicated with severe pneumonia","volume":"26","author":"Zhang","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/44.2.235","article-title":"Population pharmacokinetics of amikacin in patients with haematological malignancies","volume":"44","author":"Romano","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"106219","DOI":"10.1016\/j.ejps.2022.106219","article-title":"Amikacin pharmacokinetics in elderly patients with severe infections","volume":"175","author":"Parada","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/IDR.S150839","article-title":"High-dose amikacin for achieving serum target levels in critically ill elderly patients","volume":"11","author":"Sadeghi","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00134-013-2909-9","article-title":"Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis","volume":"39","author":"Shimamoto","year":"2013","journal-title":"Intensive Care Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2133\/dmpk.19.159","article-title":"Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity","volume":"19","author":"Nagai","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: Nephrotoxicity","volume":"43","author":"Tulkens","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11095-007-9347-8","article-title":"Natural and synthetic polymers as inhibitors of drug efflux pumps","volume":"25","author":"Werle","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00006454-199508000-00004","article-title":"Influence of malignancy on the pharmacokinetics of vancomycin in infants and children","volume":"14","author":"Chang","year":"1995","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1128\/AAC.49.12.4934-4941.2005","article-title":"Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies","volume":"49","author":"Buelga","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Dreydemy, G., Coussy, A., Lannou, A., Petit, L., Biais, M., and Carri\u00e9, C. (2021). Augmented Renal Clearance, Muscle Catabolism and Urinary Nitrogen Loss: Implications for Nutritional Support in Critically Ill Trauma Patients. Nutrients, 13.","DOI":"10.3390\/nu13103554"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/phar.1653","article-title":"Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics","volume":"35","author":"Hobbs","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ageing\/afz135","article-title":"Attention to age: Similar dosing regimens lead to different vancomycin levels among older and younger patients","volume":"49","author":"Yahav","year":"2019","journal-title":"Age Ageing"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0021-9681(72)90027-6","article-title":"Indices of relative weight and obesity","volume":"25","author":"Keys","year":"1972","journal-title":"J. Chronic Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","article-title":"The origin of the \u201cideal\u201d body weight equations","volume":"34","author":"Pai","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/2\/373\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:31:23Z","timestamp":1760121083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/2\/373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,11]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["antibiotics12020373"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12020373","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2023,2,11]]}}}